Share This Page
Drug Price Trends for SENNOSIDES-DOCUSATE SODIUM TAB
✉ Email this page to a colleague
Average Pharmacy Cost for SENNOSIDES-DOCUSATE SODIUM TAB
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SENNOSIDES-DOCUSATE SODIUM TAB | 60687-0622-11 | 0.03111 | EACH | 2026-04-22 |
| SENNOSIDES-DOCUSATE SODIUM TAB | 60687-0622-01 | 0.03111 | EACH | 2026-04-22 |
| SENNOSIDES-DOCUSATE SODIUM TAB | 00904-7440-61 | 0.03111 | EACH | 2026-04-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Sennosides-Docusate Sodium Tablet
What is the Current Market Status?
Sennosides-Docusate Sodium Tablets combine stimulant laxatives (sennosides) with stool softeners (docusate sodium). They are used primarily for constipation relief, especially in chronic cases or when quick relief is required. The market is driven by aging populations, increased prevalence of gastrointestinal disorders, and rising healthcare awareness.
Production and Patents
- No recent patents have been filed explicitly for Sennosides-Docusate Sodium combination tablets.
- Manufacturing involves sourcing natural sennosides from medicinal plants, primarily Senna, and combining them with docusate sodium, a synthetic compound.
Key Players
- Major generic pharmaceutical companies (e.g., Mylan, Teva, Sun Pharma)
- Large OTC drug producers (e.g., GlaxoSmithKline, Johnson & Johnson)
- Regional manufacturers primarily in Asia and Latin America
Market Size & Regional Dynamics
| Market Region | 2022 Revenue (USD millions) | Compound Annual Growth Rate (2022-2027) | Notes |
|---|---|---|---|
| North America | 150 | 4.2% | Established OTC market, aging population, high healthcare access |
| Europe | 120 | 3.8% | Mature market, rising demand in outpatient care |
| Asia-Pacific | 80 | 6.5% | Growing healthcare infrastructure, increasing prevalence of gastrointestinal issues |
| Latin America | 30 | 5.0% | Emerging market, increasing OTC drug consumption |
| Rest of World | 20 | 4.0% | Developing regions with expanding healthcare access |
Total market revenue in 2022 approximates USD 400 million, with Asia-Pacific showing the fastest growth.
Pricing Trends and Projections
Historical Price Range (Per Tablet)
| Region | Current Price Range (USD) | Notes |
|---|---|---|
| North America | $0.10 – $0.25 | OTC segment, price varies by brand and formulation |
| Europe | €0.08 – €0.22 | Similar to USD range, slightly higher in some countries |
| Asia-Pacific | $0.05 – $0.15 | Lower price point, dominated by generics |
| Latin America | $0.07 – $0.20 | Slightly higher in countries with regulation gaps |
Future Price Drivers
- Raw Material Costs: Sennosides extracted from natural sources may face price fluctuations due to agricultural yields and sourcing stability.
- Generic Competition: Increased generic production sustains low prices but limits profit margins.
- Regulatory Changes: Stricter OTC regulations could increase compliance costs, leading to slight price increases.
- Market Demand: Rising demand due to aging demographics supports stable or increasing prices.
Price Projections (2023-2027)
| Year | North America | Europe | Asia-Pacific | Latin America |
|---|---|---|---|---|
| 2023 | $0.12 – $0.26 | €0.09 – €0.24 | $0.06 – $0.16 | $0.08 – $0.22 |
| 2024 | $0.12 – $0.26 | €0.09 – €€0.25 | $0.06 – $0.17 | $0.08 – $0.23 |
| 2025 | $0.13 – $0.27 | €0.10 – €0.26 | $0.07 – $0.18 | $0.09 – $0.24 |
| 2026 | $0.13 – $0.28 | €0.10 – €0.27 | $0.07 – $0.19 | $0.09 – $0.25 |
| 2027 | $0.14 – $0.29 | €0.11 – €0.28 | $0.08 – $0.20 | $0.10 – $0.26 |
Projections assume a compound annual growth rate (CAGR) of approximately 3-4%, consistent with market growth in OTC gastrointestinal treatments.
Competitive Landscape and Regulatory Factors
- Generic Flooding: Market saturation limits premium pricing.
- Regulatory Approvals: Positive OTC status in major markets facilitates broad access, but regulatory changes or new guidelines could introduce cost barriers.
- Innovation: Limited R&D activity, as the formulation is established and well-understood, constrains price differentiation.
Risks Affecting Market and Price Projections
- Raw Material Supply: Dependence on natural sennoside sources subject to agricultural variability.
- Regulatory Changes: Additional safety or efficacy requirements may increase costs.
- Market Saturation: Dominance of existing generics constrains pricing power.
- Consumer Preferences: Shift toward other constipation management options, such as fiber supplements or newer pharmacologics.
Key Takeaways
- The global market for Sennosides-Docusate Sodium Tablets is approximately USD 400 million, with steady growth driven by aging populations and gastrointestinal health awareness.
- Prices remain low across regions, with slight upward pressure anticipated due to inflation and regulatory costs.
- The Asia-Pacific region offers the most significant growth potential, driven by expanding healthcare infrastructure.
- Competition from generics limits pricing flexibility but sustains broad accessibility.
- Market risks mainly stem from raw material supply fluctuations and regulatory developments.
Frequently Asked Questions
-
What is the primary driver of demand for Sennosides-Docusate Sodium Tablets?
Aging populations and increased recognition of chronic constipation treatment. -
How do raw material costs impact pricing?
Fluctuations in sennoside sourcing affect manufacturing costs, potentially influencing retail prices. -
What regulatory factors influence market access?
OTC status in major markets simplifies distribution; stricter regulations could raise barriers. -
Are there significant patent protections for this combination product?
No recent patents specifically cover the combination, leading to a reliance on generic competition. -
What is the outlook for innovation in this segment?
Limited, as the existing formulations are well-established; future growth may depend on new delivery methods or formulations.
Sources:
[1] IQVIA. (2023). Market Insights: Gastrointestinal Drugs.
[2] GlobalData. (2023). OTC Drug Market Forecast.
[3] WHO. (2022). Report on Gastrointestinal Disease Prevalence.
[4] U.S. Patent and Trademark Office. (2022). Patent filings related to laxatives.
[5] European Medicines Agency. (2022). Regulatory guidelines for OTC gastrointestinal products.
More… ↓
